Key facts
- It has raised $53.5M.
- Notable investors include Enterprise Ireland, Earlybird Venture Capital, SV Health Investors, EQT Life Sciences, EQT — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Perfuze
- ·The full record, as it builds
Funding rounds
No funding rounds for Perfuze are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Perfuze
Developer of catheter-based aspiration technology designed for the treatment of acute ischemic stroke. The company's platform provides catheter technology engineered for efficient vessel access and enhanced clot removal, enabling neuro-interventional specialists to achieve clinical outcomes in shorter procedural times and patients to get access to cost-effective therapy for ischemic stroke.
- Sector
- Healthcare
- HQ
- Galway, Ireland
- Founded
- 2018
- Employees
- 40
- Website
- perfuze.com/
- Ownership
- Privately Held (backing)
Perfuze doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Perfuze shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Perfuze in its N-PORT filings yet. We sweep new filings monthly.